Basel, 27 May 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that
James Sabry (1958), Head of Roche Pharma Partnering, will be retiring after
fourteen years with the company.
James Sabry joined Genentech in 2010 as Head of Genentech Partnering. In 2018,
he became the Head of Pharma Partnering and a member of the enlarged Corporate
Executive Committee, based in Basel, Switzerland. James Sabry completed an MD at
Queen's University in Canada and his residency at Harvard Medical School, and
then completed a PhD in neuroscience at UCSF.
Boris Zaïtra (1972), currently Head of Group Business Development, will be
appointed Head of Corporate Business Development effective 1 July 2024, a new
role that will bring together the Pharma Partnering and Group Business
Development functions. He will become a member of the enlarged Corporate
Executive Committee, reporting to Thomas Schinecker, Group CEO, and will
continue to be based in Basel.
Boris Zaïtra joined Roche in Basel in 2012 in his current role. Prior to this,
he had progressively expanding M&A leadership responsibilities in multiple
industries. He holds a Master of Sciences from Ecole Polytechnique in France.
Roche's CEO Thomas Schinecker: "James has been instrumental in forging important
deals for our Pharma R&D pipeline that have led to numerous launches of new
medicines. I am grateful for James`s contributions to our company and for his
dedication to our purpose." Schinecker further commented: "Leveraging external
innovation has always been and continues to be a critical part of our business
strategy. I am excited to have Boris Zaïtra take on this new role. He brings an
excellent combination of expertise in M&A, experience in the industry, and
leadership to the role. "
About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial
manufacturers of branded medicines, Roche has grown into the world's largest
biotechnology company and the global leader in in-vitro diagnostics. The company
pursues scientific excellence to discover and develop medicines and diagnostics
for improving and saving the lives of people around the world. We are a pioneer
in personalised healthcare and want to further transform how healthcare is
delivered to have an even greater impact. To provide the best care for each
person we partner with many stakeholders and combine our strengths in
Diagnostics and Pharma with data insights from the clinical practice.
In recognising our endeavour to pursue a long-term perspective in all we do,
Roche has been named one of the most sustainable companies in the
pharmaceuticals industry by the Dow Jones Sustainability Indices for the
fifteenth consecutive year. This distinction also reflects our efforts to
improve access to healthcare together with local partners in every country we
work.
Genentech, in the United States, is a wholly owned member of the Roche Group.
Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com (http://www.roche.com).
All trademarks used or mentioned in this release are protected by law.
Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com
(mailto:media.relations@roche.com)

  Hans Trees, PhD           Sileia Urech
  Phone: +41 79 407 72 58   Phone: +41 79 935 81 48
  Nathalie Altermatt        Simon Goldsborough
  Phone: +41 79 771 05 25   Phone: +44 797 32 72 915
  Karsten Kleine            Nina Mählitz
  Phone: +41 79 461 86 83   Phone: +41 79 327 54 74
  Kirti Pandey              Yvette Petillon
  Phone: +49 172 6367262    Phone: +41 79 961 92 50
  Dr. Rebekka Schnell
  Phone: +41 79 205 27 03

Â